Adele Blackler, Ph.D.

Adele Blackler, Ph.D., serves as the Vice President of Platform Development, specializing in mass spectrometry, oncology liquid biopsy tests, and clinical proteomic applications. She has a robust background in developing multiplex biomarker tests at various diagnostic companies, aimed at supporting therapeutic decisions for solid tumor treatments, including those for lung, colorectal, and breast cancer. Her work includes developing Laboratory Developed Tests and Clinical Trial Assays on both proteomic and genomic platforms, particularly as companion diagnostics for lung cancer therapy. Dr. Blackler earned her bachelor’s degree in chemistry from the Colorado School of Mines and her Ph.D. from the University of Colorado at Anschutz, where she focused on developing high-throughput proteomic methods for membrane proteins. Following her Ph.D., she completed a post-doctoral fellowship at the National Cancer Institute, where she developed methods integrating high throughput protein analysis with tissue microdissection. Currently, she oversees the development of new assays for detecting and quantifying gangliosides to identify disease signatures.